Literature DB >> 8378188

Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice.

W M van Weerden1, A van Kreuningen, N M Elissen, M Vermeij, F H de Jong, G J van Steenbrugge, F H Schröder.   

Abstract

The transplantable human prostate tumor lines PC-82 and PC-EW regress after androgen depletion. The castration-induced decline in tumor volume was faster in the PC-EW tumor (half-life 6 days) than in the PC-82 tumor (half-life 18 days), despite similar castrate androgen levels of less than 3 pmol/g tissue. Androgen ablation of the PC-82 tumor induced a wave of apoptosis, whereas in the PC-EW tumor, necrotic cell death was predominantly observed. The proliferative activity (BrdU index) of PC-82 and PC-EW tumor tissue declined from 3% to less than 1% after castration. After androgen depletion, some proliferative activity remained, the major part of which was localized in the (murine) stromal compartment of the tumors. In contrast to the PC-EW tumors, regrowth of androgen-ablated PC-82 tumors was rapidly induced by androgen resubstitution. The differences in response of these tumor models to androgen depletion and repletion appear to be related to the putative involvement of different cell death pathways. The role of the stroma in these processes is unclear.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8378188     DOI: 10.1002/pros.2990230208

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  13 in total

Review 1.  Human prostate cancer heterotransplants: a review on this experimental model.

Authors:  Lluis A Lopez-Barcons
Journal:  Asian J Androl       Date:  2010-04-05       Impact factor: 3.285

2.  Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation.

Authors:  R R Berges; Y Furuya; L Remington; H F English; T Jacks; J T Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

3.  Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Authors:  Maitreyee K Jathal; Liqun Chen; Maria Mudryj; Paramita M Ghosh
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011-06

4.  Development of seven new human prostate tumor xenograft models and their histopathological characterization.

Authors:  W M van Weerden; C M de Ridder; C L Verdaasdonk; J C Romijn; T H van der Kwast; F H Schröder; G J van Steenbrugge
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

5.  Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; Edson J Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 6.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

7.  Neuroendocrine differentiation in human prostatic tumor models.

Authors:  M A Noordzij; W M van Weerden; C M de Ridder; T H van der Kwast; F H Schröder; G J van Steenbrugge
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

8.  A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.

Authors:  Stephanie A Harmon; Ethan Bergvall; Esther Mena; Joanna H Shih; Stephen Adler; Yolanda McKinney; Sherif Mehralivand; Deborah E Citrin; Anna Couvillon; Ravi A Madan; James L Gulley; Ronnie C Mease; Paula M Jacobs; Martin G Pomper; Baris Turkbey; Peter L Choyke; M Liza Lindenberg
Journal:  J Nucl Med       Date:  2018-03-30       Impact factor: 10.057

9.  Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer.

Authors:  Michael F McEntee; Carol Ziegler; Danielle Reel; Kenneth Tomer; Ahmed Shoieb; Mark Ray; Xiaoou Li; Nancy Neilsen; Fred B Lih; Dorcas O'Rourke; Jay Whelan
Journal:  Am J Pathol       Date:  2008-06-13       Impact factor: 4.307

10.  Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.

Authors:  P Westin; P Stattin; J E Damber; A Bergh
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.